PepGen Inc. (PEPG) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, PepGen reported revenue of $0. Net income was -$89.7M, or -$2.12 per diluted share. Operating activities generated -$81.6M of cash, leaving -$81.9M of free cash flow. At fiscal year end, PepGen held $173.9M in total assets against $26.5M in total liabilities, including $60.5M of cash and equivalents.
Open the full interactive PepGen financials → Quarterly statements, key ratios, valuation history and price charts.
PepGen Key Stats
| Share Price | $2.50 |
|---|---|
| Market Cap | $173.0M |
| 52-Week Range | $1.35 – $7.17 |
| Shares Outstanding | 69.2 million (basic, 2026 Q2) |
PepGen Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | -$68.3M | -$84.8M | -$97.7M | -$93.6M |
| Pre-Tax Income | -$65.4M | -$78.6M | -$90.6M | -$89.6M |
| Income Tax | $3.7M | $73,000 | -$617,000 | $48,865 |
| Net Income | -$69.1M | -$78.6M | -$90.0M | -$89.7M |
| Diluted EPS | -$4.42 | -$3.30 | -$2.85 | -$2.12 |
PepGen Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$18.0M | -$18.3M | -$17.8M | -$17.8M |
| Diluted EPS | -$0.52 | -$0.43 | -$0.26 | -$0.26 |
PepGen Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $181.8M | $80.8M | $49.4M | $60.5M |
| Current Assets | $186.1M | $112.7M | $123.8M | $151.0M |
| Total Assets | $217.4M | $143.1M | $150.9M | $173.9M |
| Current Liabilities | $18.8M | $17.5M | $16.7M | $12.6M |
| Total Liabilities | $37.8M | $34.6M | $32.3M | $26.5M |
| Shareholders' Equity | $179.6M | $108.4M | $118.6M | $147.4M |
PepGen Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$59.3M | -$69.0M | -$82.4M | -$81.6M |
| Cash From Investing | -$3.8M | -$32.0M | -$37.7M | -$15.2M |
| Cash From Financing | $112.2M | -$189,000 | $88.7M | $108.0M |
| Free Cash Flow | -$63.0M | -$71.6M | -$82.9M | -$81.9M |
Figures from PepGen's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full PepGen financials page for every line item.
PepGen Company Profile
| Ticker | PEPG |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001835597 |
Frequently Asked Questions
What was PepGen's revenue in fiscal 2025?
PepGen (PEPG) reported revenue of $0 for fiscal 2025.
What is PepGen's annual revenue history?
PepGen's annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was PepGen's net income in fiscal 2025?
PepGen reported net income of -$89.7M for fiscal 2025.
What was PepGen's earnings per share (EPS) in fiscal 2025?
PepGen's diluted EPS was -$2.12 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did PepGen generate in fiscal 2025?
PepGen generated -$81.9M of free cash flow in fiscal 2025.
What was PepGen's revenue last quarter?
In its most recent reported quarter (2026 Q2), PepGen reported revenue of $0.
How many shares of PepGen are outstanding?
PepGen reported a weighted average of 69.2 million basic shares outstanding in 2026 Q2.
What is PepGen's market cap?
Based on its latest closing price, PepGen (PEPG) has a market capitalization of about $173.0M.
When does PepGen's fiscal year end?
PepGen's fiscal year end, as registered with the SEC, is December 31.
Where is PepGen headquartered?
PepGen lists its business address in Boston, Massachusetts in its SEC filings.